Implementing Negative Control Outcomes to Assess Comparability of Treatments for Psoriasis and Psoriatic Arthritis.
Horner ME, Ogdie A, Orroth KK, Kent ST, Tran KV, Deignan C, Cordey M, Brookhart MA.
Horner ME, et al.
Pharmacoepidemiol Drug Saf. 2025 May;34(5):e70156. doi: 10.1002/pds.70156.
Pharmacoepidemiol Drug Saf. 2025.
PMID: 40387023
Free PMC article.
The 1-year relative risk (RR) for each NCO was estimated for all treatment comparisons using an inverse probability of treatment and censoring weighted estimator. RESULTS: In PsO, potential healthy user bias was detected in apremilast vs. IL-17i initiators, w …
The 1-year relative risk (RR) for each NCO was estimated for all treatment comparisons using an inverse probability of treatment and censori …